We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Edwards Lifesciences (EW - Free Report) closed at $98.43, marking a +0.46% move from the previous day. This change lagged the S&P 500's 1.5% gain on the day. Elsewhere, the Dow gained 1.12%, while the tech-heavy Nasdaq added 0.32%.
Coming into today, shares of the medical device maker had gained 1.76% in the past month. In that same time, the Medical sector lost 0.3%, while the S&P 500 lost 6.54%.
Investors will be hoping for strength from Edwards Lifesciences as it approaches its next earnings release. In that report, analysts expect Edwards Lifesciences to post earnings of $0.64 per share. This would mark no growth from the year-ago period. Our most recent consensus estimate is calling for quarterly revenue of $1.4 billion, up 1.92% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.57 per share and revenue of $5.72 billion, which would represent changes of +15.77% and +9.29%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Edwards Lifesciences. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Edwards Lifesciences is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Edwards Lifesciences is currently trading at a Forward P/E ratio of 38.18. This valuation marks a premium compared to its industry's average Forward P/E of 28.28.
Meanwhile, EW's PEG ratio is currently 2.75. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. EW's industry had an average PEG ratio of 1.98 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 140, which puts it in the bottom 45% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EW in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know
In the latest trading session, Edwards Lifesciences (EW - Free Report) closed at $98.43, marking a +0.46% move from the previous day. This change lagged the S&P 500's 1.5% gain on the day. Elsewhere, the Dow gained 1.12%, while the tech-heavy Nasdaq added 0.32%.
Coming into today, shares of the medical device maker had gained 1.76% in the past month. In that same time, the Medical sector lost 0.3%, while the S&P 500 lost 6.54%.
Investors will be hoping for strength from Edwards Lifesciences as it approaches its next earnings release. In that report, analysts expect Edwards Lifesciences to post earnings of $0.64 per share. This would mark no growth from the year-ago period. Our most recent consensus estimate is calling for quarterly revenue of $1.4 billion, up 1.92% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.57 per share and revenue of $5.72 billion, which would represent changes of +15.77% and +9.29%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Edwards Lifesciences. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Edwards Lifesciences is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Edwards Lifesciences is currently trading at a Forward P/E ratio of 38.18. This valuation marks a premium compared to its industry's average Forward P/E of 28.28.
Meanwhile, EW's PEG ratio is currently 2.75. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. EW's industry had an average PEG ratio of 1.98 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 140, which puts it in the bottom 45% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EW in the coming trading sessions, be sure to utilize Zacks.com.